Infusion sets for the delivery of a therapeutic substance to a patient
US-9669156-B2 · Jun 6, 2017 · US
US10022078B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10022078-B2 |
| Application number | US-43963006-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 23, 2006 |
| Priority date | Jul 13, 2004 |
| Publication date | Jul 17, 2018 |
| Grant date | Jul 17, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates generally to biointerface membranes utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, the invention relates to novel biointerface membranes, to devices and implantable devices including these membranes, methods for forming the biointerface membranes on or around the implantable devices, and to methods for monitoring glucose levels in a biological fluid sample using an implantable analyte detection device.
Opening claim text (preview).
What is claimed is: 1. An analyte sensing device adapted for insertion into a host's soft tissue, comprising: a transcutaneous sensor comprising an in vivo portion and an ex vivo portion, wherein the sensor is configured to detect an analyte in the host, wherein the sensor comprises: a first electrode comprising an electroactive portion; a second electrode; a sensing membrane deposited on the electroactive portion, the sensing membrane comprising: a first domain comprising an enzyme configured to catalyze a reaction with the analyte; and a second domain comprising a carrier matrix storing a bioactive agent, wherein the second domain is configured to provide an interface with an in vivo environment, wherein the bioactive agent is configured to be released from the carrier matrix through a first release and through a second release to modify tissue response of the host, wherein the first release is configured to begin at a time associated with sensor insertion and end prior to end of sensor life, wherein the second release continues until end of sensor life, wherein the bioactive agent comprises dexamethasone; and a housing that houses sensor electronics configured for operable connection to sensor, wherein the sensor electronics is configured to process sensor data, and wherein the housing further comprises an adhesive pad for adhering the housing to the skin of the host. 2. The device of claim 1 , wherein the second domain comprises a biointerface configured to retain body fluid in vivo. 3. The device of claim 2 , wherein a concentration of an analyte in the body fluid is indicative of a concentration of the analyte in the host. 4. The device of claim 2 , wherein the sensor is embedded within the biointerface. 5. The device of claim 2 , wherein the biointerface comprises a plurality of pores dimensioned for fluid influx. 6. The device of claim 2 , wherein the biointerface comprises a silicone polymer/hydrophilic-hydrophobic polymer blend. 7. The device of claim 2 , wherein the biointerface comprises at least one of a fibrous material, a non-woven material, or a woven material. 8. The device of claim 2 , wherein the biointerface comprises a mesh. 9. The device of claim 2 , wherein the biointerface comprises a mechanical spacer configured to provide a protective framework around the sensor. 10. The device of claim 1 , wherein the sensor is configured to measure a signal that is indicative of a concentration of the analyte within the fluid-filled pocket. 11. The device of claim 1 , wherein the electronics are inductively coupled to the sensor. 12. The device of claim 1 , wherein the sensor is configured to generate a signal in a picoAmp range. 13. The device of claim 1 , wherein the analyte is glucose.
lymph vessels, ducts or nodes · CPC title
Apparatus specially adapted for solid-phase testing · CPC title
Needles · CPC title
invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors · CPC title
Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.